Ignite Creation Date:
2024-06-16 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06436677
Status:
RECRUITING
Last Update Posted:
2024-05-31
First Post:
2024-05-24
Brief Title:
A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma
Sponsor:
Peking University First Hospital
Organization:
Peking University First Hospital
Study Overview
Official Title:
A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AMITY
Brief Summary:
Cutaneous T-cell lymphoma CTCL is a group of diseases resulting from clonal hyperplasia of memory T cells in the skin The increasing incidence and high treatment costs have posed significant challenges to public health and the economy Current treatment guidelines only provide partial control leading to varying remission times and recurrence rates This study aims to use molecular subtyping and immunohistochemistry to guide treatment selection for CTCL patients aiming to prolong clinical benefit improve treatment safety and reduce economic burden
Detailed Description:
The study focuses on the impact of treatment strategy selection based on molecular typing for patients with cutaneous T-cell lymphoma The study aims to evaluate the effect on clinical benefit time and long-term prognosis assess the safety of the treatment strategy and explore the interaction between baseline factors and treatment regimens This research could potentially provide valuable evidence for precision treatment in the context of cutaneous T-cell lymphoma
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| SF2024-1-4074 | OTHER_GRANT | Capitals Funds for Health Improvement and Research | None |